ER positive

Using this tool and pre-existing clinical data, we identify several pathways that may be targets in driving the growth of aggressive cancers, including treatment-resistant estrogen receptor-positive breast cancer. Overall, MPOInt adds clinical context to data that is traditionally difficult to interpret and generates a unique network centered around epigenetic factors for each collection of data.

Our collective data indicate that 27HC interferes with endocrine therapy and chemotherapy in breast cancer, representing a novel mechanism of MDR. Accordingly, we propose that hypercholesterolemia or accumulation of 27HC is a potential health risk for breast cancer patients.

This case demonstrates a rare gastric metastasis in bilateral ILC in addition to a diagnostic challenge of differentiating orbital metastasis from pseudotumor.

Short-course preoperative ET induces rapid and reproducible morphological and immunophenotypic changes in ER-positive, HER2-negative breast cancer. Ki67-defined response is associated with genomic risk and PR expression, whereas microenvironmental features appear to have limited predictive value.

Obesity was associated with lower ORR with letrozole alone, whereas this association was not observed in patients treated with taselisib.

Postoperatively, he received adjuvant stereotactic radiosurgery (30-35 Gy in five fractions) to the resection cavity and was transitioned from tamoxifen to trastuzumab deruxtecan (T-DXd) for improved CNS-directed systemic therapy. Surveillance imaging at 6 months demonstrated no intracranial recurrence, and systemic restaging showed no extracranial disease progression. This case highlights the importance of prompt neuroimaging for new neurological symptoms in male breast cancer patients and supports a multimodal strategy, including surgical resection, focal radiation, and CNS-penetrant HER2-targeted therapy, for achieving durable intracranial control in select patients with isolated brain metastasis.

A transcriptional signature associated with SARM sensitivity was identified, primarily driven by proliferation-related processes, consistent with a significant decrease in S-phase cell cycle proteins upon treatment in EP0062-sensitive models. In some EP0062-resistant tumors, the combination with palbociclib enhanced the antitumor effect of EP0062, suggesting a potential strategy for metastatic patients with acquired ET resistance.

The need for chemotherapy in postmenopausal HR + , HER2- breast cancer patients might be further informed by integrating the results of the Oncotype DX test with the response to NET.

P2, N=80, Recruiting, Mayo Clinic | Trial completion date: Oct 2026 --> Sep 2027 | Trial primary completion date: Oct 2026 --> Aug 2027

Compounds 19 and 21 underscored significant human ERα inhibition in contrast to tamoxifen and bazedoxifene...Moreover, pharmacokinetics and DFT analysis ensured drug-likeness and bio-feasibility of promising molecules. Finally, based on interaction-analysis, bio-assay findings, and 3D-QSAR mapping, an overall structure-activity correlation was established for future-optimization and lead-development of indole - 4,5-dihydroisoxazole hybrids against ER+ BC.

This case demonstrates that FNH can exhibit marked FES uptake. Awareness of this benign cause of FES avidity is important to avoid misinterpreting hepatic FES-avid lesions as metastasis.

P1, N=32, Active, not recruiting, Patrick Dillon, MD | Recruiting --> Active, not recruiting